IMTX
Price:
$7.14
Market Cap:
$820.15M
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carci...[Read more]
Industry
Biotechnology
IPO Date
2018-12-12
Stock Exchange
NASDAQ
Ticker
IMTX
According to Immatics N.V.’s latest financial reports and current stock price. The company's current Enterprise Value is 646.97M. This represents a change of 7.80% compared to the average of 600.14M of the last 4 quarters.
The mean historical Enterprise Value of Immatics N.V. over the last ten years is 466.91M. The current 646.97M Enterprise Value has changed 13.76% with respect to the historical average. Over the past ten years (40 quarters), IMTX's Enterprise Value was at its highest in in the June 2024 quarter at 1.04B. The Enterprise Value was at its lowest in in the September 2024 quarter at -173176000.00.
Average
466.91M
Median
490.75M
Minimum
222.43M
Maximum
620.44M
Discovering the peaks and valleys of Immatics N.V. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 178.94%
Maximum Annual Enterprise Value = 620.44M
Minimum Annual Increase = -53.97%
Minimum Annual Enterprise Value = 222.43M
Year | Enterprise Value | Change |
---|---|---|
2023 | 564.26M | 36.68% |
2022 | 412.84M | -33.46% |
2021 | 620.44M | 178.94% |
2020 | 222.43M | -53.97% |
2019 | 483.28M | -3.00% |
The current Enterprise Value of Immatics N.V. (IMTX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
532.51M
5-year avg
460.65M
10-year avg
466.91M
Immatics N.V.’s Enterprise Value is less than Crinetics Pharmaceuticals, Inc. (4.70B), greater than ALX Oncology Holdings Inc. (89.73M), greater than BioAtla, Inc. (-24850783.00), greater than Aerovate Therapeutics, Inc. (44.29M), greater than Keros Therapeutics, Inc. (168.72M), less than Syndax Pharmaceuticals, Inc. (981.75M), greater than Mineralys Therapeutics, Inc. (520.85M), less than Replimune Group, Inc. (908.15M), less than Janux Therapeutics, Inc. (3.24B), greater than Fennec Pharmaceuticals Inc. (161.29M), less than Edgewise Therapeutics, Inc. (2.77B), less than Harmony Biosciences Holdings, Inc. (1.73B), less than Inhibrx Biosciences, Inc. (0), greater than Merus N.V. (14.97M), less than Lyell Immunopharma, Inc. (2.45B), greater than Kronos Bio, Inc. (132.63M), greater than null (7.86M),
Company | Enterprise Value | Market cap |
---|---|---|
4.70B | $4.97B | |
89.73M | $95.99M | |
-24850783.00 | $30.41M | |
44.29M | $74.87M | |
168.72M | $680.12M | |
981.75M | $1.11B | |
520.85M | $618.13M | |
908.15M | $945.52M | |
3.24B | $3.24B | |
161.29M | $169.50M | |
2.77B | $2.81B | |
1.73B | $1.94B | |
0 | $209.47M | |
14.97M | $2.89B | |
2.45B | $181.49M | |
132.63M | $57.03M | |
7.86M | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Immatics N.V. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Immatics N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Immatics N.V.'s Enterprise Value?
What is the highest Enterprise Value for Immatics N.V. (IMTX)?
What is the 3-year average Enterprise Value for Immatics N.V. (IMTX)?
What is the 5-year average Enterprise Value for Immatics N.V. (IMTX)?
How does the current Enterprise Value for Immatics N.V. (IMTX) compare to its historical average?